We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

93 hedge funds and large institutions have $244M invested in BioSpecifics Technologies Corp. in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

29% more capital invested

Capital invested by funds: $189M → $244M (+$54.3M)

21% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 28

16% more funds holding

Funds holding: 8093 (+13)

Holders
93
Holders Change
+13
Holders Change %
+16.25%
% of All Funds
2.13%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
17
Increased
34
Reduced
28
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$30.8M -$33.3K -653 -0.1%
BlackRock
2
BlackRock
New York
$28.5M +$4.22M +82,625 +20%
SCM
3
Stonepine Capital Management
Oregon
$16.7M -$8.98M -176,056 -38%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$16.4M +$502K +9,849 +4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$15.4M +$175K +3,433 +1%
RHJA
6
Rice Hall James & Associates
California
$10.6M -$1.15M -22,493 -11%
Acadian Asset Management
7
Acadian Asset Management
Massachusetts
$7.99M +$1.31M +25,634 +23%
ECP
8
Elk Creek Partners
Colorado
$6.68M -$2.43M -47,609 -29%
TAM
9
THB Asset Management
Connecticut
$6.64M -$23K -450 -0.4%
State Street
10
State Street
Massachusetts
$6.11M +$91.6K +1,796 +2%
Goldman Sachs
11
Goldman Sachs
New York
$5.6M +$16.7K +327 +0.3%
Northern Trust
12
Northern Trust
Illinois
$5.52M +$154K +3,015 +3%
EAM
13
Eagle Asset Management
Florida
$5.51M -$47.1K -924 -1%
AL
14
AJO LP
Pennsylvania
$5.06M +$254K +4,971 +6%
JAM
15
JW Asset Management
Florida
$4.31M
Prudential Financial
16
Prudential Financial
New Jersey
$4.3M -$417K -8,176 -10%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$4.11M +$14.1K +276 +0.4%
Allianz Asset Management
18
Allianz Asset Management
Germany
$4.09M +$171K +3,353 +5%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$3.74M -$30.1K -589 -0.9%
Wells Fargo
20
Wells Fargo
California
$3.69M +$564K +11,054 +21%
RA
21
Royce & Associates
New York
$3.46M -$268K -5,254 -8%
CCM
22
Cadence Capital Management
Massachusetts
$2.89M +$2.52M +49,363 New
First Manhattan
23
First Manhattan
New York
$2.77M +$408K +8,000 +20%
Charles Schwab
24
Charles Schwab
California
$2.71M -$9.29K -182 -0.4%
AQR Capital Management
25
AQR Capital Management
Connecticut
$2.56M -$2.86M -55,988 -56%

BSTC Hedge Fund Activity: Q3 2018 in Review

93 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2018, worth a combined $244M — up 29% from $189M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BSTC positions and 4 closed out — a net gain of 13 holders — while 34 added to existing stakes and 28 trimmed.

The largest buyer was BlackRock, adding an estimated $4.22M. The largest seller was Stonepine Capital Management, cutting an estimated $8.98M.

  • 93 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2018, up from 80 in Q2 2018.
  • Funds reported $244M of BioSpecifics Technologies Corp. stock for Q3 2018, up 29% quarter-over-quarter.
  • 17 funds opened new BioSpecifics Technologies Corp. positions in Q3 2018 and 4 closed out, a net change of +13 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2018 was BlackRock, an estimated $4.22M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2018 was Stonepine Capital Management, an estimated $8.98M sold.

Based on aggregated 13F filings for Q3 2018.